CoChat

Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic

Open access
de Sèze, Jérôme, Maillart, Elisabeth, Gueguen, Antoine, Laplaud, David A., Michel, Laure, Thouvenot, Eric, Zephir, Hélène, Zimmer, Luc, Biotti, Damien, Liblau, Roland · 2023 · Frontiers in Immunology
Cited by 160

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

The immune system plays a significant role in multiple sclerosis. While MS was historically thought to be T cell-mediated, multiple pieces of evidence now support the view that B cells are essential players in multiple sclerosis pathogenic processes. High-efficacy disease-modifying therapies that target the immune system have emerged over the past two decades. Anti-CD20 monoclonal antibodies selectively deplete CD20+ B and CD20+ T cells and efficiently suppress inflammatory disease activity. These monotherapies prevent relapses, reduce new or active magnetic resonance imaging brain lesions, and lessen disability progression in patients with relapsing multiple sclerosis. Rituximab, ocrelizumab, and ofatumumab are currently used in clinical practice, while phase III clinical trials for ublituximab have been recently completed. In this review, we compare the four anti-CD20 antibodies in terms of their mechanisms of action, routes of administration, immunological targets, and pharmacokinetic properties. A deeper understanding of the individual properties of these molecules in relation to their efficacy and safety profiles is critical for their use in clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2023.1004795

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 160

Metadata

Authors
de Sèze, J., Maillart, E., Gueguen, A., Laplaud, D. A., Michel, L., Thouvenot, E., Zephir, H., Zimmer, L., Biotti, D., & Liblau, R.
Venue
Frontiers in Immunology
Published
2023-03-23
Volume
14
Pages
1004795-1004795
ISSN
1664-3224 (ISSN-L)
OpenAlex
W4360619161
Cited by
160
References
22
FWCI
26.46
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. https://app.cochat.ai/papers/10.3389/fimmu.2023.1004795
The paper
de Sèze, J., Maillart, E., Gueguen, A., Laplaud, D. A., Michel, L., Thouvenot, E., Zephir, H., Zimmer, L., Biotti, D., & Liblau, R. (2023). Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1004795

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.